Michele Guida

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

Omid Hamid, Henrik Schmidt, Aviram Nissan et al. · Journal of Translational Medicine · 2011 · 530 citations · Full text

Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

Michele Maio, Karl D. Lewis, Lev Demidov et al. · The Lancet Oncology · 2018 · 210 citations · Full text

Medicine, Melanoma, Immunology +10

Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated <i>BRAF</i>-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial

Paolo A. Ascierto, Mario Mandalà, Pier Francesco Ferrucci et al. · Journal of Clinical Oncology · 2022 · 208 citations

Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis

Attila Kollár, Robin L. Jones, Silvia Stacchiotti et al. · Acta Oncologica · 2016 · 184 citations · Full text

Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study

M. De Lena, Vito Lorusso, Agnese Latorre et al. · European Journal of Cancer · 2001 · 167 citations

Advanced Ovarian Cancer, Medicine, Pharmacology +8